{Reference Type}: Journal Article
{Title}: Methionine sulfoxide reductase B2 protects against cardiac complications in diabetes mellitus.
{Author}: Lee SH;Cho S;Lee JY;Kim JY;Kim S;Jeong M;Hong JY;Kim GY;Lee SW;Kim E;Kim J;Kim JW;Hwa J;Kim WH;
{Journal}: Diabetol Metab Syndr
{Volume}: 16
{Issue}: 1
{Year}: 2024 Jul 5
{Factor}: 5.395
{DOI}: 10.1186/s13098-024-01390-0
{Abstract}: Diabetes mellitus (DM) is a progressive, chronic metabolic disorder characterized by high oxidative stress, which can lead to cardiac damage. Methionine sulfoxylation (MetO) of proteins by excessive reactive oxygen species (ROS) can impair the basic functionality of essential cellular proteins, contributing to heart failure. Methionine sulfoxide reductase B2 (MsrB2) can reverse oxidation induced MetO in mitochondrial proteins, so we investigated its role in diabetic cardiomyopathy. We observed that DM-induced heart damage in diabetic mice model is characterized by increased ROS, increased protein MetO with mitochondria structural pathology, and cardiac fibrosis. In addition, MsrB2 was significantly increased in mouse DM cardiomyocytes, supporting the induction of a protective process. Further, MsrB2 directly induces Parkin and LC3 activation (mitophagy markers) in cardiomyocytes. In MsrB2, knockout mice displayed abnormal electrophysiological function, as determined by ECG analysis. Histological analysis confirmed increased cardiac fibrosis and disrupted cardiac tissue in MsrB2 knockout DM mice. We then corroborated our findings in human DM heart samples. Our study demonstrates that increased MsrB2 expression in the heart protects against diabetic cardiomyopathy.